FGF19型
法尼甾体X受体
内科学
内分泌学
肝肠循环
生物
成纤维细胞生长因子
FGF21型
胆汁酸
成纤维细胞生长因子受体4
细胞生物学
化学
过氧化物酶体增殖物激活受体
成纤维细胞生长因子受体
G蛋白偶联胆汁酸受体
核受体
成纤维细胞生长因子受体1
受体
肝细胞
胆固醇7α羟化酶
肝星状细胞
下调和上调
分泌物
成纤维细胞生长因子受体2
转录因子
生物化学
基因
医学
作者
Holly A. Cyphert,Xuemei Ge,Alison B. Kohan,Lisa M. Salati,Yanqiao Zhang,F. Bradley Hillgartner
标识
DOI:10.1074/jbc.m112.375907
摘要
Background: The hormone FGF21 is a potent regulator of carbohydrate and lipid metabolism and a promising drug for treating metabolic syndrome.Results: Farnesoid X receptor (FXR) agonists and FGF19 induce hepatic FGF21 secretion via a transcriptional mechanism and posttranscriptional mechanism, respectively.Conclusion: Activation of the FXR pathway stimulates FGF21 expression and secretion.Significance: Activation of FXR is a potential approach to enhance endogenous FGF21 production and reverse metabolic syndrome. Background: The hormone FGF21 is a potent regulator of carbohydrate and lipid metabolism and a promising drug for treating metabolic syndrome. Results: Farnesoid X receptor (FXR) agonists and FGF19 induce hepatic FGF21 secretion via a transcriptional mechanism and posttranscriptional mechanism, respectively. Conclusion: Activation of the FXR pathway stimulates FGF21 expression and secretion. Significance: Activation of FXR is a potential approach to enhance endogenous FGF21 production and reverse metabolic syndrome.
科研通智能强力驱动
Strongly Powered by AbleSci AI